Data extraction The generic and brand names of GLP-1 RAs approved by the FDA were used to identify adverse events of GLP-1 RAs in the DRUG files, including exenatide (BYETTA, BYDUREON), liraglutide (VICTOZA, SAXENDA), dulaglutide (TRULICITY), lixisenatide (ADLYXIN, SOLIQUA), and semaglutide (OZEMPIC, RYBELSUS, WEGOVY)
! GIP: () () (GLP-1, PYY)
The business models winning in peptide therapy Final Insights Peptides are now dividing healthcare and the longevity market between those who call them miracles and those who need more research before believing any claim
Weight reduction via tirzepatide improves liver histology by reducing hepatic steatosis through sustained caloric deficit and improved insulin sensitivity the SURMOUNT trials showed significant reductions in ALT and AST alongside body weight loss